Skip to main content
UCB's Global Corporate Website
instagram
facebook
twitter
youtube
linkedin
rss
Listen
18 Jan 2022
Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study
Read More
8 Jan 2022
Disposals of own shares
Read More
3 Jan 2022
Disposals of own shares
Read More
21 Dec 2021
Disposals of own shares
Read More
16 Dec 2021
Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial
Read More
10 Dec 2021
UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis
Read More
3 Dec 2021
Disposals of own shares
Read More
3 Dec 2021
UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021 reinforcing long-standing commitment to advancing epilepsy treatment and care
Read More
2 Dec 2021
UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease
Read More
30 Nov 2021
UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases
Read More
Pagination
First page
Previous page
‹ Previous
Page
1
Current page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next ›
Last page
Subscribe to
Choose a Country
Global Site – English
Australia – English
België – Engels
Belgique – Anglais
Brasil – Português
България – Български
Canada – English
Canada – Français
中国 – 中文
Česká Republika – Angličtina
Danmark – Engelsk
Deutschland – Deutsch
France – Français
España – Español
Ελλάδα – Ελληνικά
India – English
Ireland – English
Italia – Inglese
日本 – 日本語
한국 – 한국어
Luxembourg – Anglais
Luxemburg – Engels
Magyarország – Angol
México & Latinoamérica – Español
Nederland – Engels
New Zealand – English
Norge – Engelsk
Österreich – Deutsch
Polska – Polski
Portugal – español y portugués
România – Engleză
Россия – Русский
Slovensko – Anglický
Suomi – Englanti
Sverige – Engelska
Schweiz – Deutsch
Türkiye – Türkçe
Україна – Англійська
United Kingdom – English
U.S.A. – English
×
instagram
facebook
twitter
youtube
linkedin
rss